Evidence map›Paper›PMID 40843286›Full record

ArticleAdvanced nanobiomed research2021

Evaluation of a Targeted Drug-Eluting Intravascular Nanotherapy to Prevent Neointimal Hyperplasia in an Atherosclerotic Rat Model.

Emily R Newton, David C Gillis, Kui Sun, Brooke R Dandurand, Robin Siletzky, Suvendu Biswas, Mark R Karver, Nick D Tsihlis, Samuel I Stupp, Melina R Kibbe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced nanobiomed research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emily R NewtonDepartment of Surgery, Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
David C GillisDepartment of Surgery, Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Kui SunDepartment of Surgery, Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Brooke R DandurandDepartment of Surgery, Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Robin SiletzkyDepartment of Surgery, Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Suvendu BiswasSimpson Querrey Institute, Northwestern University, Chicago, IL 60611, USA.
Mark R KarverSimpson Querrey Institute, Northwestern University, Chicago, IL 60611, USA.
Nick D TsihlisDepartment of Surgery, Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Samuel I StuppSimpson Querrey Institute, Northwestern University, Chicago, IL 60611, USA.
Melina R KibbeDepartment of Surgery, Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Funding

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
Novel Vehicles for Targeted Cardiovascular RepairR01HL116577 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KIBBE, MELINA RAE, STUPP, SAMUEL I · 2013 to 2016
$4.3M
NHLBI NIH HHS R01 HL116577NIGMS NIH HHS T32 GM086330
6 · The paper itself

Abstract

Objective: To test the hypothesis that nitric oxide-bearing collagen-targeted nanofibers will target vascular injury and inhibit neointimal hyperplasia in an atherosclerotic rat model. Approach and Results: Western blot confirms apolipoprotein E (ApoE) knockout (-/-) status. Serum cholesterol increases three-fold in Sprague Dawley (SD) ApoE-/- Conclusions: Targeted drug-eluting nanofibers localize to vascular injury, decrease neointimal hyperplasia after 2 weeks, and are durable out to 3 months in an atherosclerotic rat model.

Indexed as

arterial restenosiscollagennanofibersneointimal hyperplasianitric oxidetargeted therapeutic

Identifiers

PMID40843286
PMCPMC12366775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.